Phase 2 N=30 Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014
Phase 2 N=45 Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Leukemia
Primary: Percentage of Patients Achieving a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) on Single Agent CC-5013 at 6 Months — 68.9 percentage of…
Phase 2 N=44 Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Number of Participants With Complete Response (CR) — 14 participants
Phase 2 N=12 Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Patients With Confirmed Objective Status of Complete Response (CR), Complete Clinical Response (CCR), Nodular Partial Response (nPR), or Partial Response (PR)…
Phase 1 N=37 BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)
Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Number of Patients With Dose-Limiting Toxicities Adverse Events (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=80 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants
Phase 2 N=33 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma
Primary: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen — 0; 5; 28 participants
Phase 3 N=817 Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Leukemia
Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001
Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia
Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…
Phase 2 N=59 Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Overall Participant Response Rate: Percentage of Participants With Complete + Partial Response According to Revised National Cancer Institute-sponsored Working Group…
Phase 2 N=22 Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Complete Response Rate — 36 percentage of patients
Phase 2 N=26 Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
Chronic Lymphocytic Leukemia · Leukemia
Primary: Best Response — 20; 3; 3 Participants
Phase 2 N=41 Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Leukemia · Lymphoma
Primary: Complete Response Rate — 10 percentage of participants
Phase 2 N=104 Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With Treatment-emergent Adverse Events — 34; 34; 35; 33 Participants
Phase 2 N=21 Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 53 percentage of participants
Phase 3 N=552 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
Chronic Lymphocytic Leukemia
Primary: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC) — 660; 813 Days — p=0.0218
Phase 2 N=28 Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lymphocytic Leukemia
Primary: Clinical Response (Complete or Partial Remission) — 0; 1; 0; 3 participants
Phase 2 N=44 Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · Leukemia
Primary: Number of Patients in Overall Response Categories — 3; 1; 10; 30 Participants
Phase 2 N=21 Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)
CLL
Primary: IwCLL-WG Defined Complete Response (CR) — 1 participants
Phase 2 N=33 Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease
Chronic Lymphocytic Leukemia
Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…
Phase 2 N=418 Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: 2-Year Progression Free Survival (PFS) Rate — 0.64; 0.71; 0.74 proportion of participants
Phase 2 N=65 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants
Phase 2 N=102 Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Leukemia
Primary: Response Rate — 55.2 percentage
Phase 2 N=21 Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
Chronic Lymphocytic Leukemia (CLL)
Primary: Complete Response — 45 Percentage of Participants
Phase 2 N=36 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Lymphoid Leukemia · Small Lymphocytic Lymphoma · Lymphoma, Non-Hodgkin
Primary: Time to Progression — 4.76 years
Phase 3 N=128 A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
Lymphocytic Leukemia, Chronic
Primary: Percentage of Participants With Disease Progression (PD), Relapse, or Death Due to Any Cause Assessed According to the National Cancer Institute (NCI) Revised Guidelines…
Phase 2 N=64 Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 8; 40; 7; 41 participants
Phase 2 N=289 Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia · Leukemia
Primary: Number of Participants With Complete Remission (CR) — 185 Participants
Phase 2 N=102 Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia · Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia
Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants